Western Human Nutrition Research Center
Davis, California, 95616, United States
NCT Number: NCT03203915
To determine if the addition of chardonnay grape marc (also called pomace) powder enriched with grape seed extract to the diet will result in reducing blood levels of cholesterol or triglycerides.
Looking for future studies?
Notify Me35 year–65 year
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
Previous research on grape seed nutritional properties has predominantly been confined to grape seed extracts (GSE) containing only soluble components. In animal models, GSE has been shown to prevent increases in blood pressure, blood cholesterol, and insulin resistance. In humans, there have been improvements in blood pressure, however no significant effect on blood cholesterol levels. Whole milled grape marc flours deliver more dietary complexity than seed extracts alone. In addition to the extractable and non-extractable polyphenols, flour offers dietary fiber, minerals, sterols and polyunsaturated fats. Grape marc flour is currently used as a food ingredient that is incorporated into various baked goods. However, to obtain good control of the dose level, the product will be provided in capsule form for this study. For reference, a ½ cup of of a high polyphenol food such as blueberries, contains about 325 milligrams of polyphenols, thus even with the higher dose, participants will be receiving an amount of polyphenols that is less than ¼ cup of blueberries. The grape marc powder is prepared in a facility that is certified for producing food-grade products, and the nutritional composition and safety of the product will be thoroughly evaluated before we begin the study. The objective of the current study is to determine if this chardonnay grape marc powder enriched with grape seed extract supplementation has beneficial impacts on the human blood lipid profile and to correlate gut biome changes to human metabolism.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
Time frame: Weeks 4, 10, 16
Fasting triglyceride concentrations, LDL cholesterol, HDL cholesterol, non-HDL cholesterol will be measured in serum; postprandial triglyceride measurements (1, 2, 3 hours)
Time frame: Weeks 1, 4, 10, 16
Gut microbiota community profile will be determined by 6M read metagenomic gene sequencing from stool samples
Time frame: Weeks 4, 10, 16
Hydrogen and methane gas (parts per million) will be measured simultaneously in breath to assess gut fermentation
Time frame: Weeks 4, 10, 16
Immunological markers such as: tumor necrosis factor-α, Interleukin-β, Interleukin-6, Interleukin-1B, Interleukin-10, Interleukin-18, Interleukin-1a, Intercellular Adhesion Molecule 1, vascular cell adhesion molecule 1, C-reactive protein, Serum amyloid A, neopterin, myeloperoxidase, eotaxin, Interferon gamma-induced protein 10, Myeloid dendritic cell, monocyte chemoattractant protein 1, Matrix metalloproteinase-1, Matrix metalloproteinase-3, Matrix metalloproteinase-9 will be taken at fasting at each test day.
Time frame: Weeks 4, 10, 16
Blood pressure will be measured each test day. Endothelial function will be measured once per day using peripheral arterial tone (PAT) signal technology. Endothelial function is expressed as a Reactive Hyperemia Index (RHI).
Time frame: Weeks 1, 4, 10, 16
Fecal bile acids, plasma bile acids, fecal and plasma short-chain fatty acids
Fecal samples were taken at baseline and after each test day. Plasma samples were taken at fasting, 1, 2, and 3hrs postprandially.
Time frame: Weeks 4, 10, 16
Executive function will be assessed using Cambridge Neuropsychological Test Automated Battery (CANTAB) and Autonomic Nervous System Output.
Time frame: Weeks 4, 10, 16
Glucose and insulin measures at fasting and postprandially (1, 2, 3 hrs). this includes assessing insulin resistance and sensitivity indexes using fasting measurements.
Time frame: Weeks 4, 10, 16
Leptin, Ghrelin, Peptide YY 3-36, Glucagon-like peptide-1 at fasting and postprandial (1, 2, 3 hr)
Time frame: Weeks 4, 10, 16
Body composition by Dual energy X-ray Absorptiometry scan (radiologic exposure), body weight, waist and hip circumference, indirect calorimetry measured each visit.
Time frame: Weeks 4, 10, 16
Subjective rating measures using a visual analog scale at fasting and every 20 mins postprandially./
Time frame: Weeks 4, 10, 16
cholesterol species (e.g. VLDL, IDL, LDL, etc) identified and their particle sizes (e.g. small, medium, large) identified at fasting and 3hr postprandial
Time frame: Weeks 4, 10, 16
oxidized LDL measured at fasting and 1, 2, 3 hrs postprandial
Time frame: Weeks 4, 10, 16
Apo CIII, Apo B, Apo AI, Apo E measured at fasting and postprandial (1 and 3hr)
Time frame: Weeks 4, 10, 16
General well being via questionnaire, comprehensive metabolic panel (at fasting), fatty liver index
USDA, Western Human Nutrition Research Center
Fed
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06284681
Body Weight, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07018908
Body Weight, Dyslipidemia
Juriquilla, Querétaro, Mexico
View Trial DetailsNCT06626867
Body Weight, Cardiovascular Diseases
Taipei, Taiwan
View Trial DetailsNCT02956590
Body Weight, Dyslipidemia
Wilmington, Delaware, United States
View Trial Details